Article Type
Changed
Fri, 06/09/2023 - 11:07

Key clinical point: Patients with migraine who recovered from COVID-19 showed an increase in the frequency of headache attacks, level of anxiety, and use of antimigraine drugs.

 

Major finding: Among patients with migraine, those with vs without a history of COVID-19 showed a significant increase in the frequency of headache attacks (P = .01), level of anxiety (P = .002), and use of antimigraine drugs (P = .04) after recovering from COVID-19, with no significant difference being observed in the headache intensity (P = .51) and the dynamics of the Beck Depression scale score (P = .09).

 

Study details: Findings are from a retrospective study including 133 patients aged 18-55 years with chronic and episodic migraine and with (n = 95) or without (n = 38) a history of COVID-19.

 

Disclosures: This study did not receive any funding. The authors declared no potential conflicts of interest.

 

Source: Hrytsenko O et al. The impact of the COVID-19 pandemic on patients with migraine. SAGE Open Med. 2023 (Apr 28). doi: 10.1177/20503121231170726

Publications
Topics
Sections

Key clinical point: Patients with migraine who recovered from COVID-19 showed an increase in the frequency of headache attacks, level of anxiety, and use of antimigraine drugs.

 

Major finding: Among patients with migraine, those with vs without a history of COVID-19 showed a significant increase in the frequency of headache attacks (P = .01), level of anxiety (P = .002), and use of antimigraine drugs (P = .04) after recovering from COVID-19, with no significant difference being observed in the headache intensity (P = .51) and the dynamics of the Beck Depression scale score (P = .09).

 

Study details: Findings are from a retrospective study including 133 patients aged 18-55 years with chronic and episodic migraine and with (n = 95) or without (n = 38) a history of COVID-19.

 

Disclosures: This study did not receive any funding. The authors declared no potential conflicts of interest.

 

Source: Hrytsenko O et al. The impact of the COVID-19 pandemic on patients with migraine. SAGE Open Med. 2023 (Apr 28). doi: 10.1177/20503121231170726

Key clinical point: Patients with migraine who recovered from COVID-19 showed an increase in the frequency of headache attacks, level of anxiety, and use of antimigraine drugs.

 

Major finding: Among patients with migraine, those with vs without a history of COVID-19 showed a significant increase in the frequency of headache attacks (P = .01), level of anxiety (P = .002), and use of antimigraine drugs (P = .04) after recovering from COVID-19, with no significant difference being observed in the headache intensity (P = .51) and the dynamics of the Beck Depression scale score (P = .09).

 

Study details: Findings are from a retrospective study including 133 patients aged 18-55 years with chronic and episodic migraine and with (n = 95) or without (n = 38) a history of COVID-19.

 

Disclosures: This study did not receive any funding. The authors declared no potential conflicts of interest.

 

Source: Hrytsenko O et al. The impact of the COVID-19 pandemic on patients with migraine. SAGE Open Med. 2023 (Apr 28). doi: 10.1177/20503121231170726

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Migraine ICYMI, June 2023
Gate On Date
Tue, 01/11/2022 - 20:45
Un-Gate On Date
Tue, 01/11/2022 - 20:45
Use ProPublica
CFC Schedule Remove Status
Tue, 01/11/2022 - 20:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
364621.3
Activity ID
92996
Product Name
Clinical Briefings ICYMI
Product ID
112
Supporter Name /ID
Nurtec ODT (rimegepant) [ 5341 ]